Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

New Therapeutic Approach to Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Antibodies in the Active Phase of the Disease - Phase I/II Study to Assess the Tolerance and Efficacy of DARATUMUMAB.

NCT07110662 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT07110662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07110662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
New Therapeutic Approach to Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Antibodies in the Active Phase of the Disease - Phase I/II Study to Assess the Tolerance and Efficacy of DARATUMUMAB.
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 29, 2025
Completion date
April 29, 2029
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous adverse drug reactions (cadr), immunotherapy, toxic epidermal necrolysis